GlobeNewswire Inc.··Eyepoint, Inc.EyePoint Faces Revenue Collapse as DURAVYU AMD Trials Advance Into 2026
EyePoint reports 97% revenue decline to $0.7M in Q1 2026 amid $84.8M net loss, but maintains $223M cash runway through Q4 2027 as DURAVYU Phase 3 trials advance.
EYPTregulatory approvalretinal diseases